PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

Posted by George Bondi on Jun 9th, 2026

PicoCELA Inc. (NASDAQ:PCLA – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 126,693 shares, an increase of 1,375.2% from the May 14th total of 8,588 shares. Approximately 333.4% of the shares of the company are sold short. Based on an average daily trading volume, of 9,565,111 shares, the short-interest ratio is presently 0.0 days.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA at the end of the most recent reporting period.

PicoCELA Stock Down 11.0%

NASDAQ PCLA traded down $0.80 during trading hours on Tuesday, hitting $6.50. 21,633 shares of the company’s stock were exchanged, compared to its average volume of 4,442,103. The business’s 50 day moving average is $3.60 and its 200-day moving average is $5.15. PicoCELA has a 12-month low of $1.35 and a 12-month high of $112.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.57 and a current ratio of 2.13.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research report on Wednesday, April 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, PicoCELA currently has an average rating of “Sell”.

Check Out Our Latest Analysis on PicoCELA

PicoCELA Company Profile

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.